Endocannabinoid (N-arachidonoylethanolamine)
The principal endogenous CB1 receptor agonist; a fatty acid amide neurotransmitter implicated in mood, pain, and reward.
Abstract
Anandamide (N-arachidonoylethanolamine, AEA; CAS 94421-68-8; molecular formula C22H37NO2; molecular weight 347.53) is the principal endogenous CB1 receptor agonist, isolated by Devane and Mechoulam in 1992 (Nature). The name derives from the Sanskrit ananda (bliss). The compound is synthesized on-demand from membrane phospholipid precursors via NAPE-PLD and degraded primarily by fatty acid amide hydrolase (FAAH); the on-demand synthesis-degradation kinetics produce highly localized signaling without the persistent receptor occupation typical of conventional neurotransmitters. CB1 affinity is approximately 89 nM with full agonist activity; secondary TRPV1 and PPAR-gamma activity. Plasma half-life is on the order of minutes, extremely short owing to rapid FAAH-mediated degradation. Used as the canonical endocannabinoid in academic neuroscience and as a substrate in FAAH inhibitor research. The administration of exogenous anandamide as a drug is impractical owing to the short half-life; FAAH inhibitors (URB597, PF-04457845) are used to elevate endogenous anandamide instead.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.